Capmatinib [1029712-80-8]

Catalog number: HY-13404_100mg
Brand: MedChem Express
Packing: 100 mg
Other sizes: 5 mg
10 mM
10 mg
50 mg
200 mg
Price: € 185.00
Expected delivery time: 10 days
Quantity:

Product specifications for - Capmatinib [1029712-80-8]

Overview: 
Product group: Chemicals
Category: Other
CAS No.: 1029712-80-8
Properties: 
Purity: >98%
Molecular Formula: C23H17FN6O
Molecular weight: 412.42
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352200
Scientific information: 
Scientific info: INCB28060 is a novel orally active inhibitor (IC50=0.13 nM) of c-MET kinase. IC50 Value: 0.13+/-0.05 nM(recombinant human wild-type c-MET) [1] Target: c-Met INCB28060 potently and specifically inhibits c-MET enzyme activity, c-MET-mediated signal transduction, and the c-MET-dependent neoplastic phenotype of tumor cells . in vitro: INCB28060 exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases. This inhibitor potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET-dependent tumor cell lines [1]. in vivo: Oral dosing of INCB28060 results in time- and dose-dependent inhibition of c-MET phosphorylation and tumor growth in c-MET-driven mouse tumor models, and the inhibitor is well tolerated at doses that achieve complete tumor inhibition [1]. Activated c-MET positively regulates the activity of epidermal growth factor receptors (EGFR) and HER-3, as well as expression of their ligands. These effects are reversed with INCB28060 treatment. Toxicity: INCB28060 was well tolerated at all doses during the treatment periods, with no evidence of overt toxicity or weight loss [1]. Clinical trial: INC-280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer. Phase 1
Safety information: 
MSDS: MSDS